Sichenzia Ross Friedman Ference LLP Advises DelMar Pharmaceuticals, Inc. on $10.5M Reverse Merger and Financing
NEW YORK, March 6, 2013 (GLOBE NEWSWIRE) — New York- based securities law firm, Sichenzia Ross Friedman Ference LLP announced that it has represented DelMar Pharmaceuticals Inc. (OTC BB: DMPI), a company that focuses on the discovery and development of medicines with the potential to treat cancer patients who have been unsuccessful with modern targeted or biologic therapy, in a reverse merger and $10.5 million private placement financing which consists of a purchase price of $.80 per unit. Each unit consisted of a five-year warrant to purchase one share of common stock with an exercise price of $0.80. The Sichenzia Ross team was led by partner Gregory Sichenzia, David Manno and associate Jeff Cahlon.
Media Contact
pr@srf.law
212-930-9700
[starbox id=1]
